Biotechnology company developing systems to improve the safety of blood transfusions.
Cerus Corporation operates as a leading biomedical products company specializing in advancing blood safety through its proprietary INTERCEPT Blood System. Founded in 1991 and headquartered in Concord, California, Cerus Corporation is dedicated to developing and commercializing innovative technologies that enhance the safety of donated blood components intended for transfusion.
The cornerstone of Cerus Corporation's offerings is the INTERCEPT Blood System, designed to control biological replication and reduce the risk of blood-borne pathogens in donated blood components. This system encompasses solutions for platelets, plasma, and red blood cells, effectively inactivating pathogens and ensuring safer transfusion practices.
Cerus Corporation's INTERCEPT Blood System for platelets and plasma is specifically engineered to mitigate risks associated with blood-borne pathogens in these critical components. Similarly, the INTERCEPT Blood System for red blood cells addresses safety concerns by targeting pathogens in donated red blood cells intended for transfusion.
Additionally, Cerus Corporation extends its innovative aprproach to the production of pathogen-reduced cryoprecipitated fibrinogen complex through the INTERCEPT Blood System for Cryoprecipitation. This solution is crucial for managing bleeding disorders, including cases of massive hemorrhage associated with fibrinogen deficiency, as well as providing pathogen-reduced plasma with reduced cryoprecipitate. Cerus Corporation markets its comprehensive portfolio through a direct sales force and distribution networks across the United States, Europe, the Middle East, Latin America, and other international markets.